Demars Financial Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.73M Buy
4,778
+4,288
+875% +$4.38M 1.59% 12
2026
Q1
$451K Buy
490
+15
+3% +$15.2K 0.15% 71
2025
Q4
$511K Sell
475
-88
-16% -$84.1K 0.17% 58
2025
Q3
$429K Sell
563
-194
-26% -$144K 0.15% 65
2025
Q2
$590K Sell
757
-618,761
-100% -$481M 0.23% 46
2025
Q1
$750K Buy
619,518
+100,654
+19% +$83.8M 0.02% 70
2024
Q4
$672K Buy
518,864
+518,192
+77,112% +$429M 0.02% 69
2024
Q3
$595K Buy
672
+3
+0.4% +$2.7K 0.27% 36
2024
Q2
$606K Sell
669
-88
-12% -$70.4K 0.29% 35
2024
Q1
$589K Buy
757
+179
+31% +$127K 0.29% 38
2023
Q4
$337K Hold
578
0.18% 51
2023
Q3
$311K Hold
578
0.18% 63
2023
Q2
$271K Buy
+578
New +$242K 0.15% 66

Other funds holding LLY

Demars Financial Group's LLY Position: Q2 2026 in Review

Demars Financial Group increased its Eli Lilly (LLY) stake by 875% in Q2 2026, buying an estimated $4.38M and bringing the position to 4,778 shares worth $5.73M. The position accounts for 1.59% of the portfolio, ranked #12.

Demars Financial Group first reported a position in LLY in Q2 2023 and has held it in 13 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Demars Financial Group held 4,778 shares of Eli Lilly worth $5.73M as of Q2 2026.
  • Demars Financial Group bought 4,288 Eli Lilly shares in Q2 2026, an estimated $4.38M.
  • Eli Lilly made up 1.59% of Demars Financial Group's portfolio in Q2 2026, its #12 holding.
  • Demars Financial Group first reported a position in Eli Lilly in Q2 2023 and has held it in 13 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Demars Financial Group's 13F filing for Q2 2026, filed 21 Jul 2026.